Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Wu, Haodi  [Clear All Filters]
Journal Article
Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, Miao Y, Paige SL, Lee D, Wu H, et al. Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63.e5.
Wu H, Yang H, Rhee J-W, Zhang JZ, Lam CKeung, Sallam K, C Y Chang A, Ma N, Lee J, Zhang H, et al. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. Eur Heart J. 2019.
Tang L, Yao F, Wang H, Wang X, Shen J, Dai B, Wu H, Zhou D, Guo F, Wang J, et al. Inhibition of TRPC1 prevents cardiac hypertrophy via NF-κB signaling pathway in human pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 2018.
C Y Chang A, Pardon G, Chang ACH, Wu H, Ong S-G, Eguchi A, Ancel S, Holbrook C, Ramunas J, Ribeiro AJS, et al. Increased tissue stiffness triggers contractile dysfunction and telomere shortening in dystrophic cardiomyocytes. Stem Cell Reports. 2021.
Burridge PW, Li YFuga, Matsa E, Wu H, Ong S-G, Sharma A, Holmström A, Chang AC, Coronado MJ, Ebert AD, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016.
Kernik DC, Morotti S, Wu H, Garg P, Duff HJ, Kurokawa J, Jalife J, Wu JC, Grandi E, Clancy CE. A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. J Physiol. 2019.